Our MPV* and Mylc** cells, produced with regenerative medicine technologies, will solve the shortage of experimental cells for researches on malaria and other infectious diseases, and help researchers accelerate their experiments exponentially.

​

* We are now providing test

and pilot products and will

start full-scale production in 2020.

** We start to sell this product from 12th Dec in 2019.